The purpose of this study was to investigate the construct validity and the test-retest reliability of the willingness to pay (WTP) method for estimating health state preferences associated with side effects of antipsychotic medication. Ninety-six schizophrenia patients on antipsychotics were asked (1) how much they would be willing to pay to get rid of side effects with 100 percent probability, (2) a standard gamble (SG) question measuring utilities of patient's health state associated with side effects, and (3) their WTP to get rid of side effects based on the utility found with SG. Patients were divided into three groups based on severity of side effects. There was a significant difference between side effect severity groups for (1) the utility associated with side effects (Kruskal-Wallis [K-W] chi-square = 8.48, p = 0.014), and (2) their WTP to get rid of side effects with either 100 percent probability (K-W chi-square = 1432, p = 0.001) or based on the utility associated with side effects (K-W chi-square = 5.96, p = 0.051). There was a significant correlation between utility and the WTP based on utility (Spearman r = -0.42, p = 0.003). Because of a wide variation in side effects at the 1-month interval, we were unable to assess the test-retest reliability of SG and WTP. Our results suggest that WTP has some construct validity in valuating and measuring preferences of health states associated with side effects of antipsychotics in schizophrenia.
In an era of budget constraints, clinicians are often torn between society's need to limit health care costs and patients' need to get the best available treatment. This decision has been particularly crucial in the choice of antipsychotic medication for schizophrenia patients. An example is the recent availability of atypical antipsychotics (clozapine, risperidone, olanzapine, and quetiapine) aimed at replacing conventional antipsychotics (phenothiazines and butyrophenones). Atypical antipsychotics induce fewer side effects (Leucht et al. 1999 ) but have higher acquisition costs than conventional antipsychotics (Campbell et al. 1999; Foster and Goa 1999) . Hence, clinicians treating patients with conventional antipsychotics have to determine if the prospect of having fewer side effects is worth the higher price of atypical antipsychotics.
The relationship between cost and the value a patient places on having fewer or no side effects can be examined with a cost-benefit analysis (CBA) or a cost-utility analysis (CUA), a particular form of cost-effectiveness analysis. In CBA, there are two approaches to assigning monetary values to the benefits of health care programs: (1) the human capital approach, and (2) the contingency valuation or WTP approach. In the human capital approach, the value of the individual is assumed to be the sum of present and discounted future earnings. The human capital approach is applied when the benefits will result in a significant increase of productive activity in the future. Unfortunately, most schizophrenia patients do not return to work despite improvement in symptomatology. Other factors limit the use of the human capital approach in schizophrenia, including nonvaluation of nonproductive periods such as leisure and retirement (Thompson et al. 1984) , no estimate of cost for persons living off nonlabor income (Muller and Reutzel 1984) , difference between a person's earnings and productivity (Acton 1976) , and estimates not based on patients' valuations of benefits (Robinson 1993) . Finally, this method of valuation does not take into account the nonfinancial costs of pain and suffering specific to schizophrenia, which results in an underestimate of the total cost of illness (Muller and Reutzel 1984) .
In the WTP approach, the patient is asked how much he or she is willing to pay for a treatment that will change his or her health state. WTP is also called "contingency valuation" because the method assumes that the patient can purchase the hypothetical treatment in a contingent market. Although self-reports of schizophrenia patients about feelings and attitudes toward medications may be unreliable (Awad 1992) , they are nevertheless possible (Hogan et al. 1983; Davidhizar 1985) . The WTP approach combines the patient's preference for risk aversion, valuation of pain and suffering, and appreciation of reducing risks to health by small amounts (Muller and Reutzel 1984) . This approach has already been used to investigate the WTP for reductions in the risk of death after a heart attack (Acton 1973) , for a hypothetical cure for osteoarthritis and rheumatoid arthritis (Thompson et al. 1984; Thompson 1986 ), for being free of symptoms associated with heart disease (Chestnut et al. 1996; Kartman et al. 1996) , for continuing care accommodation for elderly people (Donaldson 1990) , and for a hypothetical intervention in chronic lung disease (O'Brien and Viramontes 1994) . The WTP approach seems more appropriate than the human capital approach because side effects secondary to antipsychotics are not usually a cause of death in schizophrenia and are not a main factor in the unemployment of these patients. Therefore, an improvement in side effects may not result in a significant change in productivity and mortality. Furthermore, the WTP approach will better reflect the pain and suffering related to the side effects. In one study (Chestnut et al. 1996) , WTP answers were consistent with actual behavior in patients suffering from angina symptoms. One drawback of the WTP approach is the relationship between the amount people are willing to pay and their level of income (Robinson 1993) . The problem may be limited if the expenditure estimated by the WTP approach is small compared to the person's total income (Robinson 1993) . In addition, WTP responses in studies using a probabilistic approach may be inconsistent (Fisher 1979) or not rational (Muller and Reutzel 1984) , most probably secondary to a lack of understanding by the subjects of the concepts and questions (Thompson 1986 ). The WTP method also assumes that subjects have a normal level of cognition and are able to envision and weigh future consequences of their decision. Impaired cognitive functioning may therefore be a major limiting factor in applying WTP in schizophrenia. However, the use of standard face-to-face survey administration protocols can improve the quality of responses. This study allowed interviewers to explain the purpose of the questions and to repeat questions, and it provided the subjects with the opportunity to revise earlier answers (Thompson et al. 1984) . Finally, because WTP responses may be biased, the response validity may be tested by using a regression model to assess whether data corroborate hypothesized relationships (Mitchell and Carson 1989; Golan and Shechter 1993; Johannesson 1993) . To our knowledge, the WTP approach has not been used with schizophrenia patients before.
In CUA, the most commonly used denominator is the quality-adjusted life-year (QALY), which is the product of the time spent in ill health or life expectancy (measured in years) and a weight called utility (U). QALY represents the equivalent number of years with full health. U is a number integrating morbidity, mortality, time, and risk preferences of subjects (Feeny and Torrance 1989) and measuring the desirability of hypothetical current or future health states (Lane 1987) . U is on a scale from 0 (death or the worst state) to 1 (healthy), representing die patient's preference for an outcome when faced with uncertainty (Sox et al. 1988) . U is defined by the Von Neumann-Morgenstera utility theory describing decision making in situations with uncertain outcomes (Von Neumann and Morgenstern 1953) . U is measured with the SG method, in which an individual's preference (or U) for a health outcome is revealed by asking the subject to choose between this outcome (a certain event) and a gamble with two possible outcomes: being in perfect health versus being dead or in a state worse than death or in the worst possible state for a limited time. Perfect health has a probability p and U equal to 1. Death or the worst health state has a probability 1 -p and U equal to 0. The probability p is varied until the subject is indifferent between the certain outcome and the gamble, at which point the preference value (or U) for the certain outcome = p X Uperfect health + (1 -p)Udeath or worst state. Because Udeath or worst state = 0, then Ucertain outcome = p. To make it easier for the subject to think in terms of probability, the SG is presented with a visual aid such as a probability wheel (Torrance 1986) or drawings (figure 1). The SG method is directly derived from the Von NeumannMorgenstern utility theory and is considered the gold standard for utility measurement. Once U has been determined, cost/QALY are calculated for each treatment alternative. The most cost-effective treatment has the lowest cost/QALY. The SG method is complex, difficult to understand, and time-consuming; therefore, other methods have been developed to measure utilities (rating scale, time trade-off, magnitude estimation, equivalence). These methods are simpler to apply but do not encompass the concept of uncertainty, a key element in the Von Neumann-Morgenstem utility theory. CBA, on the other hand, is easy to understand and to apply in decision making because results are expressed in only monetary terms.
There have been few studies measuring utilities in schizophrenia. Morss and colleagues (1993) developed a multimedia utility assessment tool using short video sequences and a digitized voice on a computer. They described side effects of antipsychotic medications and assessed utilities with visual analog scales, pairwise comparisons, and SGs for three common side effects of antipsychotic drugs (tardive dyskinesia, akathisia, and pseudo-parkinsonism). Thirty-three schizophrenia patients participated in the study and reported SG utilities of 0.84 for parkinsonism, and 0.88 for akathisia and tardive dyskinesia. These results suggest decreased quality of life associated with side effects and more distress related to parkinsonism compared to akathisia and tardive dyskinesia. In a subsequent study, Lenert and colleagues (1997) used the same methodology in 41 healthy subjects and 22 schizophrenia patients. Seventy percent of patients stated that they understood the task. Only 61 percent had a consistent rank ordering of preferences among SG and pairwise comparison ratings. Chouinard and Albright (1997) asked 100 psychiatric nurses to assign utilities to health states corresponding to schizophrenia patients who had mild, moderate, or severe symptomatology and who were taking placebo, haloperidol, or risperidone. Risperidonetreated patients had a higher gain in utilities compared to haloperidol-and placebo-treated patients. Revicki and colleagues (1996) asked 49 schizophrenia patients and their primary caregivers to assign preferences for their current health state using categorical rating scales. Physicians rated the health states using SG and categorical rating scales. Although patient preferences were comparable to clinician and caregiver preferences (mean U = 0.67 for patients and 0.66 for caregivers and clinicians), patients did not rate their health states using SG in this study. To our knowledge, no study has asked schizophrenia patients to assign preferences for their current health state using SG.
The purpose of this study was to validate and test the reliability of the WTP to assess changes in patients' wellbeing associated with side effects of antipsychotics in schizophrenia. Because we were not able to compare hypothetical WTP to real-life WTP (i.e., how much a patient would pay in a real-life situation), we assessed the construct validity by looking at the association between WTP and severity of side effects. The WTP validity as a measure of preferences was assessed by examining the relationship between WTP and SG utilities (convergence validity) because, as stated above, SG is considered the gold standard for utility measurement We assessed WTP for a hypothetical medication that would get rid of side effects for 1 year under condition of certainty (100% probability of getting rid of side effects) (WTP1) and condition of uncertainty (there is a chance that side effects would get much worse) (WTP2). WTP2 is closer to a reallife situation in which a patient decides to pay for a medication knowing that this medication carries a risk. WTP test-retest reliability was assessed at a 1-month interval. We expected that (1) WTP would be higher in patients with more bothersome side effects, (2) WTP under condition of uncertainty would be lower than WTP under condition of certainty, (3) WTP under condition of uncertainty would be negatively correlated with SG (i.e., patients will be willing to pay more to improve health states associated with lower utilities), and (4) there would be a positive correlation between SG and WTP results at the 1-month interval.
Method
Ninety-eight patients with a diagnosis of schizophrenia (DSM-IV criteria, American Psychiatric Association 1994) were interviewed by one of the authors (S.S. or K.N.). All patients were described by the staff and chart review as having stable symptoms for more than 1 month. Most of the patients were service connected (100% disability paid by the Department of Veterans Affairs), single, nonworking veterans and were hospitalized at the time of the interview. Hence, members of our sample had a similar level of income, and WTP answers were not influenced by changes in work performance or household wealth (Chestnut et al. 19%) .
After signing a consent form, each patient was asked to provide information about his or her source of income and spending, total income, and available income (i.e., income after paying for basic needs, such as rent, clothes, food). Patients were also asked about their knowledge of prices for common objects (e.g., stamps, soda, newspaper, glass of water) to test their understanding of costs. Level of cognition was measured with the Mini Mental State Examination (MMSE; Folstein et al. 1975) . Symptoms were rated with the Positive and Negative Syndrome Scale (PANSS; Kay et al. 1987) . Each patient answered a set of questions about his or her hospitalization, medications, and side effects related to the antipsychotic medications.
Each patient was interviewed about side effects that he or she was currently experiencing, using a method described by Finn and colleagues (1990) . First, patients were asked about side effects with an open-ended ques-tion. Then, patients were asked if they experience specific side effects. The list of side effects was based on those reported in Finn and colleagues (1990) . Information about each side effect was recorded in the patient's own words on index cards. These were then shuffled and handed one by one to the patient, who placed them in front of five boards marked (1) "it doesn't bother me at all," (2) "it bothers me a little," (3) "it bothers me more than a little but not a lot," (4) "it bothers me a lot," (5) "it bothers me greatly." Reliability was assessed by pairing of side effects. After all the index cards had been placed before markers, the interviewer randomly picked two cards and asked the patient to name which side effect he or she had ranked higher. Four pairings were presented. Patients who failed one comparison were presented three additional pairings and had to rate them correctly to meet the reliability criteria.
Patients were divided into three groups based on the severity of side effects. If all scores on side effects were below 3, the patient was classified as mild. If at least one score was 3 and no score was more than 3, the patient was classified as moderate. If at least one score was 4 or 5, the patient was classified as severe.
The interviewer then placed the index cards in front of the patient and asked him or her what he or she would be willing to pay for a medicine that would get rid of all side effects for 1 year (WTP1). Before answering the question, patients were reminded about their level of available income and expenses and were encouraged to give a reasonable answer (i.e., an answer compatible with their level of available income). WTP questions were open-ended to avoid a starting point bias, and followup questions were used to probe inconsistencies (Chestnut et al. 1996) . Inconsistencies were defined as WTP amounts being more than available income. Patients were given the opportunity to change their answer. The WTP1 question appears in appendix 1, and the WTP2 question appears in appendix 2.
Patients were then asked an SG question estimating utilities for having side effects for 1 year. The scenario for the SG question was standardized and is described in appendix 2. Variations in probabilities for SG were presented to the patient with the help of drawings (figure 1). Once the indifference probability (or U) was obtained, patients were asked how much they would be willing to pay for a drug that would get rid of all their side effects with a Upercent chance but that would also carry a (1 -U) percent chance of leaving them bedridden for 1 year.
After answering the WTP and SG questions, subjects were asked to give their understanding of the questions in their own words (comprehension). Answers and level of understanding were determined by two of the authors (K.N. and S.S.). WTP and SG responses were analyzed only in subjects having a good understanding of the questions. Ninety-eight patients participated in the study. One patient withdrew his consent after completing the first interview, and another patient gave unreliable answers in rating side effects. Both patients were excluded from analysis. For the test-retest reliability, we conducted an interview similar to the first one in patients who were still hospitalized and on the same medication regimen 1 month after the first interview (n = 30).
Because of the skewed distribution of WTP and SG values, nonparametric statistical tests were used for analysis of WTP and SG data.
Results
Characteristics of our sample are described in table 1. At the time of the study, 62 patients were on conventional antipsychotics, 32 patients on atypical antipsychotics (either risperidone or clozapine), and 2 patients on a combination of conventional and atypical antipsychotics. Because there were no differences between patients on conventional and atypical antipsychotics for demographics, WTP values, and SG values, both groups were analyzed together. During the first interview, 96 patients were able to score their side effects in a reliable fashion. Values for side effects are reported in table 2. Six patients did not answer WTP and SG questions; two patients answered WTP1 but not SG. Four patients gave a utility of 1 and did not answer WTP1 or WTP2. Fifty-one patients answered both WTP1 and WTP2. WTP1 was statistically correlated with WTP2 (Spearman's r = 0.70, p < 0.01). WPT2 was also significantly lower than WTP1 (paired sample t test, t = 3.06, p < 0.05). Eighty-four patients answered both SG and WTP1. Thirty patients gave a WTP1 more than 0 despite a utility of 1. Thirty-nine patients had a utility less than 1 and answered WTP1 as well as WTP2. Thirty patients had a second interview 1 month later and were used for the test-retest reliability analysis.
Patients were divided into three severity groups: mild (n = 13), moderate (n = 15), and severe (n = 68). Characteristics of the entire sample and each severity group are reported in table 1. There was no statistical difference between severity groups for age, age of onset, length of illness, years of education, monthly income, MMSE scores, and PANSS scores. Because there was a significant correlation between WTP1 and available income (Spearman's r = 0.3, p < 0.05), we analyzed WTP1 and WTP2 as a percentage of income. There was a significant difference between severity groups for SG (K-W chi-square = 8.48, p = 0.014), WTP1 (K-W chi-square = 14.32, p = 0.001), and WTP2 (K-W chi-square = 5.96, p = 0.051). The correlation between SG and WTP1 was not statistically significant. Among patients who answered WTP2 (n = 51), SG was significantly correlated with WTP2 (Spearman's r = -0.42, p = 0.003). There was a wide variation in side effects reported at the 1-month interval. Consequently, test-retest reliability was not measured because WTP and SG answers were associated with different health states.
Discussion
Our results suggest that WTP has some construct/convergence validity to measure health state preferences. As expected, we found (1) higher WTPl and WTP2 as well as lower SG for patients with more severe side effects, (2) WTP under condition of uncertainty (WTP2) to be lower than WTP under condition of certainty (WTPl), and (3) a significant negative correlation between WTP under condition of uncertainty and SG utilities. Patients with severe side effects were ready to pay an average of 6 percent of available income to get rid of side effects with a 100 percent probability and an average of about 3 percent of available income if there was some risk of getting worse and bedridden for 1 year. By asking patients their WTP for their present health state, we avoided a hypothetical bias (O'Brien and Viramontes 1994): patients were asked to value probabilistic health outcomes associated with health problems and therapies with which they were familiar. This may explain our positive results for construct/convergence validity. However, due to variations in side effects reported at the 1-month interval, we were unable to assess the test-retest reliability for SG and WTP. A better way to assess the test-retest reliability would be to describe precisely the health state at the time of the first interview and to use a vignette describing that health state for the second interview.
Our study had several limitations. By classifying patients in the severe subgroup only if the rating of at least one side effect is 4 or 5, we assumed an equal weight for each side effect Patients may be severely bothered by one side effect but only mildly bothered by it when all the side effects are considered. Our study did not include a rating for a general level of bothersomeness. We also assumed that level of bothersomeness is the only factor determining health state preferences. WTP may also be affected by "positive effects" (e.g., feeling of euphoria, detachment, increased libido), which were not measured. Furthermore, some patients may benefit from having side effects: they can claim an impaired functioning and collect disability income. Despite being bothered by side effects, they may be concerned about losing disability benefits and may give a lower WTP to retain their current income levels (O'Brien and Gafni 1996) . We were able to verify only State and Federal income, which may be only part of the total income. Finally, our study did not include an external validation (i.e., WTP in a real-life situation). It has been suggested that hypothetical WTP tends to overestimate true WTP (O'Brien and Gafni 1996) .
In the SG method, we define 0 as being the worst possible state induced by side effects. Although some side effects (agranulocytosis, neuroleptic malignant syndrome) Note.-Gl = gastrointestinal. 1 Side effect was not reported In Finn and colleagues (1990) .
can result in death, we did not use death as an anchor value 0. Our objective was to develop a realistic question because death secondary to side effects is highly unlikely in a hospital setting. Furthermore, the purpose of this study was to examine the relationship between SG and WTP and not to define "true" SG utilities. Hence, our utilities will need to be adjusted in order to be compared to utilities with death as an anchor value. Our SG question included a measure of social preference ("Do you think doctors in this hospital should also try this medication with their patients?") followed by a measure of individual preference ('Tf you were one of those patients, would you take it?"). AH patients but one gave similar answers to both questions, indicating congruence between social and personal preferences and validating the correlation between SG and WTP, which is a measure of personal preference. There was a substantial number of patients with U = 1 (n = 30) who were nonetheless willing to pay to get rid of side effects. These patients may have utilities between 0.9 and 1, which we were not able to detect. These patients may also be risk-aversive and not willing to take any risk unless the level of bothersomeness is substantial. Our drawings for the SG question have not been used previously. Concerned about impairment in abstract thinking in schizophrenia, we decided not to use a probability wheel. Finally, because each subject was started at 100 or 0 and then proceeded monotonically to the point of expressed indifference, each subject's result may be biased by the starting point. This problem was partially overcome by randomly selecting the starting point, thereby eliminating bias in group-level comparisons. However, the incorporation of opposite biases in the individual-level SG values would tend to decrease the magnitude of correlation coefficients with variables not incorporating such bias (e.g., WTP measures). Accordingly, our findings of construct and convergent validity, based on correlations that are null biased in our design, are conservative. Thus, future studies will have to address the validity and reliability of different instruments for measuring probabilities in schizophrenia patients. This is to our knowledge the first study exploring techniques of contingent valuation and utility measurement by asking schizophrenia patients to assess their current health state. We have shown the feasibility of applying WTP and SG with these patients. The relationship between WTP and SG utilities suggests a relationship between CBA and CUA. Finding evidence of such relationship is essential because CBA has several advantages over CUA: CBA is easier to understand, allows determination of the net benefit of a treatment and comparison of programs between health care and non-4iealth care sectors, and can be used for public budgeting as well as insurance premium calculation (O'Brien and Gafhi 1996) . However, our conclusions have to be tempered by the limitations of our study and our inability to test the reliability of our results. Future studies will have to address these issues, which should ultimately improve the delivery of care among patients with severe psychiatric disorders.
Let us suppose that we have a medication to get rid of all the side effects you are experiencing [index cards with side effects are placed in front of patient]. This medication is only available for 1 year of treatment After discontinuing this medication, you will have the same side effects that you have now. Would you consider taking this medication? [If yes, then:] Let us suppose that the VA does not pay for it; are you willing to pay? Based on your present income and expenses, how much would you be willing to pay to take this medication for 1 year?
Appendix 2 SG question to estimate utilities related to side effects of current health state and willingness to pay under condition of uncertainty: [Showing corresponding drawing:] Let us suppose that there are 10 patients in another hospital with the same mental problem and the same side effects that you have. These patients want to get rid of their side effects and they have decided to take a new medication so they will get rid of their side effects. They have agreed to take that medication for 1 year. Afterwards, they will go back to their first medication and be as they were before trying this new medication. After starting the new medication, x out of 10 patients have no more side effects and stay free of side effects during the time they take the medication. However, (10 -x) out of 10 patients have a bad reaction to the medication. He/she has a worsening of side effects such that he/she becomes bedridden and unable to do any kind of activity for 1 year. Knowing the risk of this medication, do you think doctors in this hospital should also try this medication with their patients? [If yes:] If you were one of those patients, would you take it? [Repeat die question after changing die x to x -1 (if x = 9) or x + 1 (if x = 1). x is either 9 or 1. The choice between 9 and 1 is random.]
Willingness to pay under condition of uncertainty (WTP2):
If the VA does not pay for it, are you willing to pay? Based on your income and expenses, how much are you willing to pay to take this medication for 1 year?
